Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK

• Published in: Expert opinion on drug delivery Vol. 14; no. 12; p. 1439
• Main Authors: Pollock, R F, Muduma, G
• Format: Journal Article
• Language: English
• Published: England 02.12.2017
• Subjects: Anemia, Iron-Deficiency - drug therapy; Anemia, Iron-Deficiency - etiology; Budgets; Disaccharides - administration & dosage; Ferric Compounds - administration & dosage; Glucaric Acid - administration & dosage; Hematinics - administration & dosage; Hematinics - economics; Hematinics - therapeutic use; Humans; Inflammatory Bowel Diseases - complications; Infusions, Intravenous; Iron-Dextran Complex - administration & dosage; Maltose - administration & dosage; Maltose - analogs & derivatives; Retrospective Studies; United Kingdom; iron; Great Britain; intravenous; costs and cost analysis; Iron deficiency anemia; administration
• ISSN: 1744-7593
• DOI: 10.1080/17425247.2017.1393412

Iron deficiency is the leading cause of anemia in patients with inflammatory bowel disease (IBD). Intravenous iron is the first-line treatment for clinically active IBD or previous oral iron intolerance. The aim of the present study was to develop a comparative model of iron deficiency and delivery for iron isomaltoside (IIM), ferric carboxymaltose (FCM), low molecular weight iron dextran (LMWID), and iron sucrose (IS) in the treatment of iron deficiency anemia associated with IBD. Areas covered: A model was developed to evaluate iron delivery characteristics, resource use and costs associated with IIM, FCM, LMWID and IS. Iron deficiency was modeled using dosing tables and retreatments were modeled based on a pooled retrospective analysis. The analyses were conducted over 5 years in patients with IBD with mean bodyweight of 75.4 kg and hemoglobin levels of 10.77 g/dL based on observational data. Expert opinion: The modeling analysis showed that using IIM required 1.2 infusions (per treatment) to correct the mean iron deficit, compared with 1.6, 1.2, and 7.1 with FCM, LMWID and IS, respectively. Costs were estimated to be 2,518 pounds sterling (GBP) per patient with IIM or LMWID, relative to GBP 3,309 with FCM or GBP 14,382 with IS.